We would love to hear your thoughts about our site and services, please take our survey here.
I notice your EBMO Mol Med link is from 2018, relax!
I felt myself getting excited so decided to do some historical research myself. These snippets are from the Business Update RNS on 27th May 2020. It's very old now, I know, but I thought it would be OK because it's still well within your accepted time range:
"-- Negotiations regarding the out-licensing of pan-Asian rights to the Company's NXP002 programme are progressing well, albeit at a slower pace than expected as a result of the COVID-19 situation. The Directors are pleased with progress to date and look forward to further positive discussions in the coming months."
"The leadership team and Board have completed a business review, mapping out a sensible course through the months ahead and focussing investment on the programmes we believe will deliver short-term returns, in particular the completion of a pan-Asia out-licensing agreement for our NXP002 programme. The Company is in position to progress development programmes as soon as negotiations are complete"
Unfortunately DG had to move on a month later, which along with Covid probably delayed the negotiations a bit further but the good news is Covids over and he's been back 18 months so maybe we'll hear something about out-licensing progress any day now?
I wouldn't be so sure Chab.
However, if anyone feels themselves becoming beguiled by the historic illusions then take a cold shower by re-reading the RNS's since the start of 2020. Once you've had the reality check, continue to wait patiently for DG to bear tangible fruits from his 18 months of being in a position of employing his detailed knowledge of previous development strategies & commercial discussions to benefit Nuformix shareholders.
I bet he can't wait to be in a position to enlighten us. He must have lots to say on the subject by now!
"I'm not in the red"
Are you really feeling confident about that boast?
You started posting around mid June. I'll wager you bought in around then too. The mid price wasn't that far from todays closing bid, if I remember rightly.
As it now seems to be the norm to post old, outdated guff to try and pump the price, I decided to take a little time to looking back fondly over some of the RNS we've had. This excerpt from March 2022 on the appointment of the new business development consultant:
"Commenting on his appointment, Dr Gooding said: ".....My detailed knowledge of previous development strategies, commercial discussions and continued commitment to the success of the project and the Company will now be brought to bear in a formal way, alongside the Nuformix team, for the benefit of the NXP002 programme and the Company's shareholders."
Still looking forward to that happening after all this time! Looks like they'll get those resolutions passed before they have to announce any BD progress now. Perhaps not a bad thing for any mysterious 'big insti' that might be lurking , waiting to snap up more shares Doubt they'd want that price to go up too much beforehand!
Anyway, I digress. Here's another gem from the same release, this time from our esteemed Chairman:
"Furthermore, our search for a new CEO is progressing well and I look forward to announcing an appointment in due course."...yes mate!
He then resigned 2 months later.
Happy days!
If you weren't so busy trying to be the defensive loyal lapdog all the time then you might actually realise that by "for whatever reason" I actually do mean "for whatever reason". That could actually include something positive, believe it or not.
No they can't change the ERS deadlines but they can manipulate their own. They could have pulled all the stops out to meet those deadlines if the company's finances depended upon a big promotion at such an event.
Either they aren't that good at forward planning or they don't need to go to the expense or the effort...for whatever reason.
That would have been my thinking Jiving.
I would have expected them to be eager to showcase such remarkable results and that presenting at the ERS again would have been a top objective.
I guess it's just not that important to them, for whatever reason.
I didn't say "if its not happened by now", I said "if no one is interested by now". That process might be underway and yet to be disclosed. At least that is what I hope. If they are not talking to any interested parties now, given their association with various people from AZ and the like then I don't see how they are going to be able to raise the kind of money needed to change things themselves.
If NXP002 is all that it is touted to be then it has to be on big pharmas radar by now. If not then why not?
I want to see the company move into the hands of someone who can actually do something with it...as soon as possible. They have said they are in the position to move into BD now. That should mean interest and progress very soon, shouldn't it? So why would we want to see a massive dilutory rights issue instead?
The most likely outcome of simply tapping mugs like us for more money is that the pressure will be removed and we'll be floundering around for several more years with little direction and change of fortune. A license deal might at least reinvigorate things and at best give some investors a viable opportunity to get out and move on.
It staggers me just how many fellow posters on this board are quick to suggest that people should just throw the towel in and FO if things aren't going to their liking. I personally think we've seen enough of that behaviour from the numerous ex-directors of this company who have done exactly that over the last 3 years!
Whereas repeatedly posting old articles in the attempt to paint a picture that everything is hunky dory is a good thing? Some might say that could be misleading to potential investors too.
Ramping and de-ramping are two sides of the same coin. Both equally as bad and done to satisfy personal agendas.
Buyer beware both of them.